TCT 2018: Medtronic's CoreValve Proves Durable Out To Five Years
The five-year results from the US pivotal high-risk trial of Medtronic's CoreValve transcatheter aortic valve, the longest-term follow-up data from a randomized trial of CoreValve, show the valve remains durable with low rates of severe hemodynamic structural valve deterioration compared to surgical valves.
You may also be interested in...
The approval, based on the results of the SURTAVI trial, comes a few months ahead of analysts' expectations and is welcome news for Medtronic in its effort to keep pace with TAVR leader Edwards in the US market.
ACC 2016 BEST OF THE REST: Surgery Trials, More CoreValve Data, Leadless Pacemakers, Drug-Filled Stents, And More
Almost 19,000 people were in Chicago April 2-4 for the 2016 American College of Cardiology's Annual Scientific Sessions, which featured over 2,400 presentations, including 24 late-breaking trials and 10 other clinical research presentations. Edwards’ transcatheter valves grabbed most of the headlines, but here are some of the other highlights from medical device trial results presented at the meeting
BD and BioMedomics will soon begin distributing a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.